Functional linc-POU3F3 is overexpressed and contributes to tumorigenesis in glioma

Guo, Hua; Wu, Lei; Yang, Qing; Ye, Minhua; Zhu, Xingen

doi:10.1016/j.gene.2014.10.038

Cited by 67 publications

(53 citation statements)

References 43 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…lncRNAs have important functions in disease, including epigenetic, transcriptional, and posttranscriptional regulation [2]. Recent studies have reported lncRNA dysregulation in various cancer types [3–6].…”

Section: Introductionmentioning

confidence: 99%

BRAF-activated lncRNA predicts gastrointestinal cancer patient prognosis: a meta-analysis

Fan

et al. 2016

Oncotarget

Self Cite

View full text Add to dashboard Cite

BRAF activated non-coding RNA (BANCR) is often dysregulated in cancer. We performed a meta-analysis to clarify its functions as a prognostic indicator in malignant tumors. We searched the PubMed, Medline, OVID, Cochrane Library, and Web of Science databases to identify BANCR-related studies. Nine original studies and 898 total patients were included in the meta-analysis. Hazard ratios (HR) and 95% confidence intervals (CI) were extracted from the included studies to determine the relationship between BANCR expression and patient overall survival (OS). Odds ratios (OR) were calculated using RevMan 5.3 software to assess associations between BANCR expression and pathological parameters. High BANCR expression correlated with lymph node metastasis (LNM) (OR = 3.41, 95% CI: 1.82–6.37, P = 0.0001), distant metastasis (DM) (OR = 2.98, 95% CI: 1.76–5.07, P < 0.0001), tumor stage (OR = 3.11, 95% CI: 1.89–5.12, Z = 3.25, P < 0.0001), and poor OS (pooled HR = 1.98, 95% CI: 1.20–3.27, P = 0.008) in gastrointestinal (GI) cancer patients, but not in non-GI cancer patients. Our results support the notion that BANCR as a promising prognostic biomarker in Chinese patients with GI cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

BRAF-activated lncRNA predicts gastrointestinal cancer patient prognosis: a meta-analysis

Fan

et al. 2016

Oncotarget

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, high TUG1 expression is associated with a family history of ESCC and upper segmental esophageal cancer occurring between the esophageal inlet and upper edge of the manubrium (11). Linc-POU class 3 homeobox 3 (POU3F3) has been characterized as a highly conserved functional transcription regulator in ESCC, which promotes the methylation of POU3F3 by interacting with EZH2 (12,13).…”

Section: Cancer-related Lncrnasmentioning

confidence: 99%

“…Additionally, the uc.283-plus lncRNA may be important in the biology of glioma (55). Overexpression of linc-POU3F3 increases cell viability and proliferation in glioma (12). However, overexpression of CASC2 inhibits the malignancy of glioma cells via negatively regulating miR-21, subsequently affecting proliferation, migration, invasion and cellular apoptosis (23).…”

Section: Cancer-related Lncrnasmentioning

confidence: 99%

LncRNAs and cancer

Zhang

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Long non-coding RNAs (lncRNAs) are a group of non-coding RNAs composed of >200 nucleotides. Recent studies have revealed that lncRNAs exert an important role in the development and progression of cancer. In this review, the involvement of the most extensively investigated lncRNAs in cancers of the digestive, respiratory, reproductive, urinary and central nervous systems are discussed. LncRNAs function via molecular and biochemical mechanisms that include cis-and trans-regulation of gene expression, epigenetic modulation in the nucleus and post-transcriptional control in the cytoplasm. Although the detailed biological functions and molecular mechanisms of the majority of lncRNAs remain to be elucidated, this review aims to provide a novel insight into the diagnosis and treatment of cancer using lncRNAs.

show abstract

“…Despite advances in cancer treatment, this statistic has not changed significantly (2,3). Previous reports have suggested that several genes contribute to the pathogenesis of glioma, including protein-coding genes (4,5), microRNAs (miRNAs) (6) and long non-coding RNAs (lncRNAs) (7,8). However, the mechanisms of the majority of genes in glioma remain to be elucidated.…”

Section: Introductionmentioning

confidence: 99%

“…Accumulating evidence has shown that lncRNA expression profiling may facilitate the diagnosis and prognosis of human cancer, including bladder cancer (17), leukemia (18), breast cancer (9) and rectal cancer (19), suggesting that lncRNAs may serve as effective therapeutic targets for intervention. Previous evidence indicates that lncRNAs are important in the pathogenesis of glioma, including HOTAIR (20), H19 (21) and Linc-POU3F3 (8 been annotated, only a few lncRNAs have been functionally characterized in glioma. Nuclear factor IA (NFIA), a member of the NFI family, is essential in glial development in the central nervous system; it specifies glial identity, maintains glial progenitors and regulates astrocyte differentiation (22,23).…”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNA RP5-833A20.1 inhibits proliferation, metastasis and cell cycle progression by suppressing the expression of NFIA in U251 cells

Kang

Nie

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. Early reports suggest that nuclear factor IA (NFIA) is important in the pathogenesis of glioma. Our previous study demonstrated that the long non-coding RNA (lncRNA), RP5-833A20.1, suppressed the expression of NFIA in THP-1 macrophage-derived foam cells. However, the effect and possible mechanism of RP5-833A20.1 on glioma remains to be fully elucidated, and whether the NFIA-dependent pathway is involved in its progression has not been investigated. In the present study, the mechanisms by which RP5-833A20.1 regulates the expression of NFIA in glioma were investigated. The expression levels of RP5-833A20.1 and NFIA were determined in U251 cells and clinical samples using reverse transcription-quantitative polymerase chain reaction (PCR) analysis. The effects of RP5-833A20.1 on cell proliferation, invasion, cell cycle and apoptosis were evaluated using in vitro assays. The potential changes in protein expression were investigated using western blot analysis. The methylation status of the CpG island in the NFIA promoter was determined using bisulfite PCR (BSP) sequencing. It was found that the expression of RP5-833A20.1 was downregulated, whereas the expression of NFIA was upregulated in glioma tissues, compared with corresponding adjacent nontumor tissues from 20 patients with glioma. The overexpression of RP5-833A20.1 inhibited proliferation and cell cycle progression, and induced apoptosis in the U251 cells. The mRNA and protein levels of NFIA were markedly inhibited by overexpression of RP5-833A20.1 in the U251 cells. The overexpression of RP5-833A20.1 increased the expression of microRNA-382-5p in the U251 cells. The BSP assay revealed that the overexpression of RP5-833A20.1 enhanced the methylation level of the NFIA promoter. These results demonstrated that RP5-833A20.1 inhibited tumor cell proliferation, induced apoptosis and inhibited cell-cycle progression by suppressing the expression of NFIA in U251 cells. Collectively, these results indicated RP5-833A20.1 as a novel therapeutic target for glioma.

show abstract

Functional linc-POU3F3 is overexpressed and contributes to tumorigenesis in glioma

Cited by 67 publications

References 43 publications

BRAF-activated lncRNA predicts gastrointestinal cancer patient prognosis: a meta-analysis

BRAF-activated lncRNA predicts gastrointestinal cancer patient prognosis: a meta-analysis

LncRNAs and cancer

Long non-coding RNA RP5-833A20.1 inhibits proliferation, metastasis and cell cycle progression by suppressing the expression of NFIA in U251 cells

Contact Info

Product

Resources

About